<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504189</url>
  </required_header>
  <id_info>
    <org_study_id>CLP1000</org_study_id>
    <nct_id>NCT03504189</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety of PregSense™ and Compare Its Performance to CTG in Prenatal Monitoring of Pregnant Subjects</brief_title>
  <official_title>Clinical Study Evaluating the Safety of PregSense and Comparative Performance of PregSense Versus CTG in Prenatal Monitoring of Pregnant Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvo-Group, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvo-Group, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the safety of PregSense™ and Comparative Performance of
      PregSense™ versus CTG in Prenatal Monitoring of Pregnant subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PregSense™ is a maternal-fetal monitor that non-invasively measures and displays fetal heart
      rate, maternal hear rate and uterine contractions. This study will be performed to collect
      and digitally record data from PregSense™ and the standard of care (CTG) in order to provide
      evidence of safety and agreement between PregSense™ and the gold standard NST device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">November 8, 2018</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal Heart Rate</measure>
    <time_frame>30 Minutes</time_frame>
    <description>Provide evidence of safety and FHR agreement between PregSense™ and the standard of care devices (i.e. CTG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal Heart Rate</measure>
    <time_frame>30 MInutes</time_frame>
    <description>Provide evidence of safety and agreement between MHR collected via the PregSense™ and the standard of care devices (i.e. CTG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine Contractions</measure>
    <time_frame>30 Minutes</time_frame>
    <description>Compare uterine contractions from Pregsense™ versus CTG.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Measures</measure>
    <time_frame>Through study completion, an average of 1 hour</time_frame>
    <description>Evaluate device related adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>PregSense™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PregSense™</intervention_name>
    <description>PregSense™ wearable device will be applied for maternal-fetal monitoring</description>
    <arm_group_label>PregSense™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiotocopraphy (CTG)</intervention_name>
    <description>Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring</description>
    <arm_group_label>PregSense™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age between 18-50

          -  Gestational age &gt; 32 + 0 weeks

          -  Singleton gestation

          -  Ability to understand and sign informed consent

        Exclusion Criteria:

          -  BMI (Body Mass Index) ≥ 45 and ≤15 prior pregnancy

          -  Multiple gestation

          -  Uncontrolled Hypertension

          -  Fetal Anomaly

          -  Subjects with skin problems in the abdominal area (such as flesh wounds, cuts in the
             skin, skin rashes, etc.)

          -  Subjects with implanted electronic devices (pacemaker, defibrillator, etc.)

          -  Subjects who, in the judgement of the investigator, are likely to be non-compliant or
             uncooperative during the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Womens Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <results_first_submitted>January 13, 2019</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fetal monitoring, Prenatal monitoring</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03504189/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>&quot;PregSense™ and Cardiotocopraphy (CTG)&quot;</title>
          <description>PregSense™ WSB then was applied by the authorized study personnel to the maternal abdominal area, not before cleaning the maternal abdomen with a damp cloth, then drying the abdomen. Before initiating the recording session, a valid signal is to be obtained.
An authorized study personnel applied the CTG transducers and confirmed fetal heart rate detection according to the standard of care procedure.
If a valid signal was detected, a 30-minute session initiated, recording both systems simultaneously in a synchronized method (PregSense™ and CTG).
Following the completion of the sessions, the authorized study personnel removed both monitoring systems from the maternal abdomen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PregSense™</title>
          <description>PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
PregSense™: PregSense™ wearable device will be applied for maternal-fetal monitoring
Cardiotocopraphy (CTG): Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fetal Heart Rate</title>
        <description>Provide evidence of safety and FHR agreement between PregSense™ and the standard of care devices (i.e. CTG)</description>
        <time_frame>30 Minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>&quot;PregSense™ and Cardiotocopraphy (CTG)&quot;</title>
            <description>PregSense™ wearable device was applied for maternal-fetal monitoring</description>
          </group>
          <group group_id="O2">
            <title>Cardiotocopraphy (CTG)</title>
            <description>Philips FM30 (CTG) was applied for maternal-fetal monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Heart Rate</title>
          <description>Provide evidence of safety and FHR agreement between PregSense™ and the standard of care devices (i.e. CTG)</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.3" spread="11.9"/>
                    <measurement group_id="O2" value="140.4" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maternal Heart Rate</title>
        <description>Provide evidence of safety and agreement between MHR collected via the PregSense™ and the standard of care devices (i.e. CTG)</description>
        <time_frame>30 MInutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PregSense™</title>
            <description>PregSense™ wearable device was applied for maternal-fetal monitoring</description>
          </group>
          <group group_id="O2">
            <title>Cardiotocopraphy (CTG)</title>
            <description>Philips FM30 Cardiotocopraphy (CTG) was applied for maternal-fetal monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Heart Rate</title>
          <description>Provide evidence of safety and agreement between MHR collected via the PregSense™ and the standard of care devices (i.e. CTG)</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="12.54"/>
                    <measurement group_id="O2" value="89.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uterine Contractions</title>
        <description>Compare uterine contractions from Pregsense™ versus CTG.</description>
        <time_frame>30 Minutes</time_frame>
        <population>Uterine Contraction information was eventually not collected AT ALL, therefore no population to describe.</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;PregSense™ and Cardiotocopraphy (CTG)&quot;</title>
            <description>PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
PregSense™: PregSense™ wearable device will be applied for maternal-fetal monitoring
Cardiotocopraphy (CTG): Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Contractions</title>
          <description>Compare uterine contractions from Pregsense™ versus CTG.</description>
          <population>Uterine Contraction information was eventually not collected AT ALL, therefore no population to describe.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Measures</title>
        <description>Evaluate device related adverse events</description>
        <time_frame>Through study completion, an average of 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PregSense™</title>
            <description>PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
PregSense™: PregSense™ wearable device will be applied for maternal-fetal monitoring
Cardiotocopraphy (CTG): Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measures</title>
          <description>Evaluate device related adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 minutes during Non stress test (NST)</time_frame>
      <desc>No adverse events reported during the trial</desc>
      <group_list>
        <group group_id="E1">
          <title>PregSense™</title>
          <description>PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
PregSense™: PregSense™ wearable device will be applied for maternal-fetal monitoring
Cardiotocopraphy (CTG): Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical</name_or_title>
      <organization>Nuvo Group</organization>
      <phone>+972-3-6242266 ext 1630</phone>
      <email>adar.shani@nuvocares.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

